68Ga-MY6349 PET/CT in Solid Tumors

Launched by THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY · Jun 23, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new scanning method called 68Ga-MY6349 PET/CT to help detect a specific protein called Trop-2 on tumor cells in people with solid tumors (a type of cancer that forms lumps or masses). The goal is to see if this scan can safely and accurately show where tumors are and help doctors decide which patients might benefit from treatments targeting Trop-2.

Adults aged 18 and older with suspected, new, or previously treated solid tumors may be eligible to join, as long as they are scheduled for standard imaging tests and can give informed permission to participate. Pregnant women or those who cannot consent are not eligible. Participants will undergo the new PET/CT scan in addition to their usual imaging tests. This scan is noninvasive, meaning it does not involve surgery or needles beyond those needed for the scan itself, and it helps doctors get a clearer picture of the tumor’s characteristics without extra discomfort.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - (i) adult patients (aged 18 years or older); (ii) patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled both standard-of-care imaging and 68Ga-MY6349 PET/CT scans; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
• Exclusion Criteria:
• • - (i) patients with pregnancy; (ii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.